Abstract Neoadjuvant (or induction) chemotherapy can be used for cervical cancer patients with locally advanced disease; this treatment is followed by radical surgery and/or radiation therapy. Cisplatin is considered to be the most active platinum agent drug for this cancer, with a response rate of 20%. In order to understand how the cisplatin treatment affects the stress response, in this work, we performed an exploratory study to analyze a number of stress proteins before and after cisplatin neoadjuvant chemotherapy. The study involved 14 patients; the pre-and post-chemotherapy paired biopsies were examined by hematoxylin and eosin staining and by immunohistochemistry. The proteins evaluated were p53, P16/INK4A, MSH2, nuclear protein transcriptional regulator 1 (NUPR1), and HSPB1 (total: HSPB1/t and phosphorylated: HSPB1/p). These proteins were selected because there is previous evidence of their relationship with drug resistance. The formation of platinum-DNA adducts was also studied. There was a great variation in the expression levels of the mentioned proteins in the pre-chemotherapy biopsies. After chemotherapy, p53 was not significantly affected by cisplatin, as well as P16/INK4A and MSH2 while nuclear NUPR1 content tended to decrease (p = 0.056). Cytoplasmic HSPB1/t expression levels decreased significantly following cisplatin therapy while nuclear HSPB1/t and HSPB1/p tended to increase. Since the most significant changes following chemotherapy appeared in the HSPB1 expression levels, the changes were confirmed by Western blot. The platinum-DNA adducts were observed in HeLa cell in apoptosis; however, in the tumor samples, the platinum-DNA adducts were observed in morphologically healthy tumor cells; these cells displayed nuclear HSPB1/p. Further mechanistic studies should be performed to reveal how HSPB1/p is related with drug resistance. When the correlations of the markers with the response to neoadjuvant chemotherapy were examined, only high pre-chemotherapy levels of cytoplasmic HSPB1/p correlated with a poor clinical and pathological response to neoadjuvant cisplatin chemotherapy (p = 0.056) suggesting that this marker could be useful opening its study in a larger number of cases.
Introduction
In Argentina, there are approximately 3000 new cases of cervical cancer every year, whereas in Latin America and other low-income countries, this disease is among the most frequent cancers affecting mainly socially vulnerable women (Arrossi 2008; Ferlay et al. 2012; Tadessse 2015) . Cervical cancer is a human papillomavirus HPV-related disease; practically all cases of cervical cancer are preceded by persistent infections with oncogenic subtypes of HPV (WHO 2016) . In Argentina N. Real, G. N. Castro, and F. D. Cuello-Carrión have contributed equally to this work.
as well as in other countries, a vaccine against HPV has been included in the immunization program expecting to decrease the incidence of cervical cancer (Arrossi et al. 2012) . Unfortunately, more years are needed to see the effect of immunization and many patients with cervical cancer are still diagnosed at late stages of the disease, for example when the cancer is locally advanced. Radiotherapy with concomitant platinum-based chemotherapy is the standard treatment for locally advanced disease but the response rate is still poor; these patients frequently show incomplete local control, disease recurrence, and distant metastasis particularly in patients with a large tumor burden, with lymph node metastasis, and/or with parametrial infiltration (Pearcey et al. 2002; Al-Mansour and Verschraegen 2010) . In order to improve the patient's outcome, an alternative treatment for these patients is the use of neoadjuvant chemotherapy followed by radical surgery and treatment completion with radiochemotherapy (Al-Mansour and Verschraegen 2010; Luvero et al. 2016) . The aim of the neoadjuvant treatment is to reduce the tumor volume rendering radical surgery feasible and at the same time kill the possible micrometastasis. The advantages and disadvantages of the addition of neoadjuvant chemotherapy to standard treatment have been analyzed recently by Narayan et al. (2016) . These authors found a better clinical response when neoadjuvant chemotherapy was applied; however, about 40% of the patients still showed a poor outcome.
In cervical cancer patients, the main drug used in neoadjuvant and adjuvant treatments is cisplatin. This drug is effective against various cancer types producing cross-links of purine bases on the DNA [90% are 1,2-intrastrand d(GpG) adducts] with important consequences: DNA damage, activation of DNA repair mechanisms, blocking cell division, and inducing apoptosis (Dasari and Tchounwou 2014) . Cisplatin toxicity is also due to oxidative stress since the compound induces reactive oxygen species that can result in both apoptosis and necrosis; this and other mechanisms of cisplatin action have been reviewed elsewhere (Dasari and Tchounwou 2014; Fong 2016) . Among the mechanism of cisplatin resistance, we can mention reduced uptake or retention of the drug by the tumor with decreased platinum-DNA adduct formation. Cisplatin exposure induces a stress response in the cells and therefore can awake a heat shock protein (HSP) and stress protein response. The participation of HSPs in DNA repair pathways and their implications in cancer therapy and drug sensitivity have been reviewed (Nadin and Ciocca 2010) . In order to expand our understanding of the stress response following cisplatin exposure, in the present report, we have performed an exploratory study to analyze particular stress proteins in biopsies from patients with locally advanced cervical cancer receiving cisplatin neoadjuvant chemotherapy. The study involved 14 patients, the pre-and post-chemotherapy paired biopsies were examined by hematoxylin and eosin staining (H&E) and by immunohistochemistry (IHC); in 5 cases, Western blot was also used. In addition, the formation of cisplatin-DNA adducts was evaluated in the pre-and postchemotherapy biopsies. The proteins evaluated were HSPB1 (also known as HSP27) (total: HSPB1/t and phosphorylated form: HSPB1/p), MSH2, nuclear protein 1 transcriptional regulator (NUPR1), p53, and P16/INK4A; these proteins were selected because there is evidence that they are related to drug resistance. For instance, in a recent study, we have reported interactions between HSPB1 and the MSH2 (DNA repair protein) and the potential role of these proteins on temozolomide resistance mechanism in human gliomas (Castro et al. 2015) . Mismatch repair proteins are important in the processing of cisplatin-DNA cross-links (Dasari and Tchounwou 2014; Sawant et al. 2015) . NUPR1 is a multifunctional stressinduced protein (Cano et al. 2011 ) implicated in pancreatic oncogenesis and in protecting cells from stress by inhibiting apoptosis (Hamidi et al. 2012 ). Chemoresistance has been described as enhanced in breast cancer cells through the NUPR1-PI3K/Akt-phospho-p21 axis in p53-negative cells (Vincent et al. 2012) , and this protein has been implicated with gemcitabine resistance in pancreatic ductal adenocarcinoma cells (Palam et al. 2015) . During stressful situations, p53 modulates particular subsets of genes driving the cells to growth arrest followed by survival or toward apoptosis, and has been implicated in platinum resistance (Thakur and Ray 2016) and in DNA double-strand break (DSB) repair pathway choice (Moureau et al. 2016) . P16/INK4A has been implicated in chemotherapy resistance in osteosarcoma patients (Robl et al. 2015) ; in contrast, in malignant pleural mesothelioma patients, high P16/INK4A levels correlated with a better survival after chemotherapy (cisplatin is among the drugs of choice to treat mesothelioma patients) (Jennings et al. 2015) . Moreover, P16/INK4A has been described as a requirement for cisplatin resistance in human cervical carcinoma SiHa cells (Li et al. 2015) . It is therefore important to study the effects of cisplatin in cancer patients to know the response mounted by the cells with the aim to find biomarkers to predict resistance to the drug avoiding the administration of chemotherapy with lack of benefits.
Patients and methods

Patients
From May 2011 to September 2016, 14 patients with locally advanced cervical cancer (stages 1B2-3B) were considered eligible and thus included for this study. Patients were required to have histological proof of invasive carcinoma, to be at least 18 years of age, have a performance status of 90% by the Karnofsky scale, serum biochemical markers within the normal range, and a normal cardiac and renal function. The patients were assessed to be metastasis free at the time of diagnosis by careful clinical evaluation, and by abdominal and pelvic computed axial tomography. None of the patients had previously received any treatment for the disease. The main clinical and pathological characteristics of the patients are shown in Table 1 . All indications were discussed in a multidisciplinary oncology meeting and the informed signed consent was obtained from the patients according to our research ethics requirements approved by the Ethic Committee of the Argentine Foundation for Cancer Research of Mendoza in accordance with the precepts established by the Helsinki Declaration.
Neoadjuvant chemotherapy
Initial diagnosis was made by a small surgical biopsy under colposcopic examination (pre-chemotherapy biopsy). Once the presence of the tumor was confirmed, the patients received two cycles of cisplatin neoadjuvant chemotherapy (100 mg/ m 2 administered in 4 days); the treatment was repeated at 21 days. The post-chemotherapy biopsies were taken at day 5 after the second neoadjuvant treatment, the samples were paraffin-included after formalin fixation, and in five cases an additional sample was taken and stored frozen for Western blot. Although the experimental conditions ended after neoadjuvant chemotherapy, we are briefly mentioning the treatments to complete the therapy after neoadjuvant chemotherapy. The patients received complete removal of the tumors (Wertheim-Meigs operation) and/or radiotherapy (50-60 Gy). After these treatments, patients were evaluated by positron emission tomography; those without evidence of disease were periodically controlled while those with evidence of disease received chemotherapy (taxanes and/or carboplatin according to the performance status).
Immunohistochemistry
Pre-and post-chemotherapy samples were immediately fixed in 10% buffered formalin and embedded in paraffin. Serial 5 -μ m -t h i c k s e c t i o n s w e r e m o u n t e d o n t o 3 -aminopropyltrietoxysilane (Sigma, St. Louis, MO, USA) coated slides for subsequent analysis. The primary antibodies and their dilutions are presented in Table 2 . The rabbit polyclonal antibody against HSPB1 (HSP25/27) was kindly provided by Dr. M. Gaestel (Max-Delbrück Center for Molecular Medicine, Berlin, Germany). The rabbit polyclonal antibody against specific intrastrand platinum-DNA adducts was kindly provided by Dr. M.C. Poirier (NIH, USA). The platinum-DNA adducts are persistent for many months in human tissues subsequent to cisplatin treatment (Poirier et al. 1992) . The specificity of the antibody was increased by absorption of the antibody (diluted 1:100 in dilution buffer: 0.02 M NaPO 4 H 2 , 0.15 M NaC1, 0.04% sodium azide, 1% BSA, pH 7.6) with DNA, adding 20 μl of Salmon Testes DNA (phenol-chloroform extract, 10 mg/mL, Sigma) to 1000 μl of the diluted antibody. After 48 h of incubation at 4°C, the antibody was centrifuged at 10,000 rpm for 20 min, and the supernatant used at a final dilution of 1:2000. For this antibody, the slides were pre-incubated with 2 M HCl followed by heat for antigen retrieval (30 min each step); this protocol gave the most successful immunostainings. The evaluation was done by subtractive comparative immunohistochemistry (pre-and post-chemotherapy). In addition to the antibodies presented in Table 2 , antibodies against low and high molecular weight cytokeratins 35H11 and 34BE12 and against CD45 (from Dako) were applied only to those samples with difficulty to identify the tumor cells in the post-chemotherapy biopsies. Before adding the antibodies, the tissue sections were treated with heat for antigen retrieval (pH 6). Tissue sections were incubated with the primary antibodies overnight at 4°C in humidity chambers. We used, as second antibody, biotinylated anti-rabbit and anti-mouse IgG (whole molecule) followed by avidin and biotinylated horseradish peroxidase complex (Vector Laboratories, Inc., Burlingame, CA, USA) at 1:200 dilutions (45 min). Diaminobenzidine (DAB, Vector Lab.) was used as chromogen substrate according to the manufacturer's instructions. Slides were lightly counterstained with hematoxylin and observed with a Nikon Eclipse E200 microscope. Sections from the serial biopsies (pre-and postchemotherapy) were always processed together. Nonspecific mouse IgG1 antibody and purified rabbit pre-immune serum (Dako, Kingsgrove, NSW, Australia) were used as isotypenegative controls. All of the slides were reviewed and scored separately by two observers who were blinded to the clinical outcome of the patients; discordant cases were re-evaluated and resolved by consensus. The samples were evaluated in intensity and proportion of cells with positive immunoreactions using a scoring system reported previously (Elledge et al. 1993) . Briefly, the intensity score used was no staining = 0, weak staining = 1, moderate staining = 2, and strong staining = 3; the proportion score used was <1% = 0, 1-10% = 1, 11-30% = 2, 31-66% = 3, and >66% = 4.
Western blot analysis
Western blot analysis was performed on pre-and postchemotherapy biopsies stored at −70°C. Tissue samples were homogenized with lysis buffer (25 mM Tris-HCl, pH 7.5, 5 mM ethylenediamine tetraacetic acid, pH 7.5, 250 mM NaCl, 1% Triton X-100) and centrifuged 30 min to 13,000 rpm at 4°C. The protein lysate (40-60 μg per lane) from the supernatant was subjected to electrophoresis on 12.5% SDS-polyacrylamide gels (w/v) and transferred to nitrocellulose filters, as previously described (Fanelli et al. 1998) . One lane was loaded with a positive control (cytosol containing HSPB1). Molecular weight markers (Rainbow Protein Markers, Amersham) were myosin (200 kDa), phosphorylase b (97.4 kDa), BSA (69 kDa), ovalbumin (46 kDa), carbonic anhydrase (30 kDa), trypsin inhibitor (21.5 kDa), and lysozyme (14.3 kDa). The nitrocellulose filters were blocked with 5% BSA in PBS and 0.05% Tween 20 (v/v) and incubated with the primary antibody described in Table 2 . After incubation overnight at 4°C, the filters were incubated with biotinylated rabbit antibody to mouse immunoglobulins. The secondary antibody was purchased from Dako (Glostrup) and was used at a dilution of 1:2500 for 90 min. Then the filters were incubated with peroxidaselabeled streptavidin-biotin complex at a dilution of 1:5000 for 45 min to detect the proteins immunoenzymatically. The bands were developed using chemiluminescence reagents according to the manufacturer's instructions (Dupont NEN, Boston, MA).
Treatment of HeLa cells
Human cervical cancer HeLa cells obtained from ATCC were cultured in DMEM media with the addition of 10% fetal bovine serum (FBS) (Internegocios S.A., Buenos Aires). When they reached 85% of confluence, the cells were subjected to serum-free media containing the following treatments: 0, 25, 50, and 100 μM cisplatinum (Filaxis Laboratories, Argentina) during 4 h. The selected doses were previously described by Sottile et al. (2015) . The cells were fixed in 4% buffered formalin and treated for immunohistochemistry.
Statistical analyses
The Wilcoxon signed-rank nonparametric test was used to determine whether differences found in the pre-and postchemotherapy biopsies were significant. Fisher's exact test and Welch t test were used to determine whether the expression of the markers studied correlate with the clinical and pathological response of the patients. Statistical analyses were performed using R version 3.3.1, and a p = 0.05 was considered statistically significant. 
Results
The clinical response to neoadjuvant chemotherapy was evaluated under colposcopic examination re-evaluating the clinical stage of the disease at day 5 after the second cycle of cisplatin therapy. The pathological response to neoadjuvant chemotherapy was evaluated in the paired biopsies assessing in the H&E stained sections the effects of chemotherapy: presence of massive apoptosis, necrosis, and cytological changes in the tumor cells, mitotic and apoptotic indexes. Both the clinical and pathological responses are presented in Table 1 . After neoadjuvant chemotherapy, the clinical response (tumor stage) and the pathological response correlated significantly (13/14, 93%). We mention here that in a large study performed on cervical cancer patients, the clinical response to neoadjuvant chemotherapy appeared as an independent predictor of disease-free survival .
We then evaluated the immunostainings in the paired preand post-chemotherapy biopsies. Examples of the findings in case #1 corresponding to a patient with poor clinical and pathological response (Table 1) are shown in Fig. 1 . The significant changes appeared in the expression of HSPB1, the total content of this protein decreased after chemotherapy at the cytoplasmic level while its expression increased at the nuclear level which corresponded to the phosphorylated form of the protein (Fig. 2) .
A similar situation was noted in a patient with good clinical and pathological response (case #2, Table 1 ) where again the total content of HSPB1 decreased after chemotherapy while the expression of HSPB1/p increased in the nuclei of the tumor cells (Fig. 3) . The other molecular markers did not change significantly in this patient.
A summary of the comparative changes in the proteins analyzed in all of the studied patients is shown in Fig. 4 . In those cases where it was difficult to identify the presence of tumor cells in the post-chemotherapy biopsies, we performed immunohistochemistry with antibodies against high and low molecular weight cytokeratins and against CD45; no tumors cells were found in cases # 5, 9, and 14 (they are not shown in Fig. 4) . Our finding revealed that cisplatin treatment induced a significant decrease in the content of cytoplasmic HSPB1/t (p = 0.021). Other changes showed marginal significance and were (a) a decrease in the nuclear NUPR1 levels and (b) an increase in nuclear HSPB1/t and HSPB1/p levels. No significant changed were noted in the other markers.
Since the most significant changes following chemotherapy appeared in the HSPB1 expression levels, the changes were confirmed by Western blot using the antibody that detected both the non-phosphorylated and the phosphorylated forms of the protein (Fig. 5) .
HeLa cells were treated with cisplatin to confirm that we were able to detect the platinum-DNA adducts (Fig. 6 ). In the clinical samples, the visualization of the platinum-DNA adducts was clear in some samples but not in others (Fig. 6 ). We were expecting to observe the platinum-DNA adducts in all the tumor tissues following chemotherapy but this was not the case; at present, we do not have a clear explanation for this inconsistency. In this figure, we can also observe relatively high Regarding the correlations of the molecular markers with the clinical and pathological response of the tumors to neoadjuvant chemotherapy, we first analyzed the pre-chemotherapy levels of markers: none of these markers showed significant correlations except for high HSPB1/p cytoplasmic levels which correlated with a poor response to chemotherapy (Fig. 7) . We then analyzed the changes after chemotherapy finding no correlations with the response to chemotherapy. Chemotherapy Fig. 4 Expression levels of the molecular markers in the paired pre-and post-chemotherapy biopsies. a MSH2 (nuclear), P16/ INK4A (nuclear), NUPR1 (nuclear), and p53 (nuclear). Note that in most of the samples, the levels of these markers suffered little modifications following chemotherapy. b HSPB1/t (cytoplasmic and nuclear) and HSPB1/p (cytoplasmic and nuclear). Note that the cytoplasmic levels of HSPB1/t decreased after chemotherapy, while the HSPB1/t and HSPB1/p nuclear levels increased (Wilcoxon test) >
Discussion
Our study revealed that in patients with advanced cervical cancer, cisplatin neoadjuvant chemotherapy can induce significant changes in HSPB1 expression levels. The total content of the protein tended to decrease, its phosphorylation increased, and the protein was relocated from the cytoplasm to the nucleus. All of the patients received cisplatin chemotherapy, so we can state that this anticancer drug is responsible for these changes. In previous works, the expression of HSPB1 has been reported as changed by several anticancer drugs like doxorubicin or epirubicin in breast cancer (Vargas-Roig et al. 1998; Nadin et al. 2014) , temozolomide in glioma cells (Castro et al. 2015) , and gemcitabine in pancreatic cancer cells (Taba et al. 2010; Kang et al. 2015) . The effect of cisplatin on HSPB1 has also been reported, for example in ovarian cancer cells HSPB1 (and HSPA) have been found up-regulated in cisplatin resistant cells, and the cells were more sensitive to the anticancer drug when HSPB1 levels were decreased (Yamamoto et al. 2001) . Cisplatin induced the expression of HSPB1 (total) in HSC-2 (oral squamous carcinoma) and A549 (lung cancer) cells but not in 16HBE14o-(normal bronchial epithelial cells), IFN-γ administration suppressed the induction of HSPB1 by cisplatin facilitating tumor cell death (Oba et al. 2008) . Cisplatin induced HSPB1 (total) expression in human hepatocellular carcinoma cells and the protein has been involved in cytoprotection by the unfolded protein response to cisplatin-induced apoptosis (Chen et al. 2011) . Cisplatin induced HSPB1 phosphorylation via p38 MAPK in drugresistant oral squamous cancer cells, and when quercetin was administered (suppressing HSPB1/p), apoptosis was increased (Chen et al. 2012) . More recently, a modest increase of HSPB1 protein levels has been reported after cisplatin treatment in mesenchymal stem cells harvested from bone marrow samples of healthy donors, the changes in HSPB1 and other HSPs have been linked to cisplatin resistance (Nicolay et al. 2016 ). These authors have not evaluated the HSPB1 protein localization and/or its phosphorylation status. In contrast to the previous studies, Stope et al. (2016) and TOV-21G); interestingly, increased extracellular HSPB1 levels were noted after chemotherapy administration in SK-OV-3 cells.
Therefore, from our results and from those mentioned above, it seems clear that (a) in cultured tumor cells, the HSPB1 protein levels (including protein phosphorylation) are modulated by cisplatin administration; (b) the modulation of HSPB1 by cisplatin differs according to the different cancer cell types; and (c) the HSPB1 appears implicated in cisplatin resistance. Mechanistically, we are tempted to speculate that when HSPB1 is decreased in the cytoplasm by phosphorylation and hence translocated to the nucleus, the HSPB1 releases client proteins, loses its antiapoptotic properties, and the tumors cells are more prone to dying. However, this scenario does not fit well with our findings; we clearly observed tumor cells with very low or no cytoplasmic HSPB1 content and with high nuclear HSPB1 levels and these cells survived 2 cycles of cisplatin as shown in Fig. 6 . It is still not clear how the HSPB1 is related to drug resistance. Ovarian cancer cells transfected with HSPB1 siRNA have shown a significantly lower ability to form colonies after exposure to paclitaxel compared with cells treated with paclitaxel alone (Song et al. 2009 ). The authors related this effect with increasing production of reactive oxygen species. HSPB1 interacts with several client proteins; in a previous study, we reported that HSPB1 Our results stress that both, the total content of HSPB1 at cytoplasmic level and the HSPB1 phosphorylation status implicated in HSPB1 localization into the nucleus, are important to regulate the behavior of the cancer cells. Our results are in agreement to those of Kang et al. (2015) who have reported that the ratio of phosphorylated/ nonphosphorylated HSPB1 (rather than the cellular level of HSPB1 itself) acts biphasically as a cell signal for survival or death depending on the stress intensities in gemcitabineresistant pancreatic cancer cells. The consequences of HSPB1 phosphorylation in cancer have been reviewed elsewhere (Katsogiannou et al. 2014) .
In contrast to in vitro studies, we found very few reports relating HSPB1 with cisplatin in cancer patients. One of them was performed in locally advanced esophageal adenocarcinoma patients that received neoadjuvant chemotherapy with 5-fluorouracil/cisplatin; the authors reported that a negative and weak staining for HSPB1 was associated with non-response to neoadjuvant chemotherapy; however, a survival disadvantage for patients with negative/weak HSPB1 staining could not be shown (Langer et al. 2008 ). The other study was performed in patients with retinoblastoma; HSPB1 cytoplasmic immunoreactivity increased significantly in the tumor cells after chemotherapy with carboplatin, etoposide, and vincristine, suggesting that these cells were protected against the cytotoxic drugs ( Kase et al. 2009 ). In these previous reports, the authors did not study the phosphorylation status of HSPB1 and there are important differences in the tumor types; in esophageal adenocarcinomas and in retinoblastomas, the initial HSPB1 levels (before chemotherapy) are lower than in squamous cervical carcinomas (Puy et al. 1989; Doak et al. 2014 , and the present study). Of interest here is also that in multivariate analysis performed in patients with esophageal squamous cell carcinomas, negative HSPB1 levels (immunostaining in <20% of the cells) predicted a good effect of radiotherapy and chemoradiotherapy (with cisplatin/nedaplatin/5-fluorouracil) (Miyazaki et al. 2005) . They found that other molecular markers (p53, p21, bax, bcl2, and HSP70) were not as reliable as HSPB1. A previous study performed on peripheral blood lymphocytes reported that in platinum-treated patients, the HSPB1 nuclear/cytoplasmic ratio was related to disease-free survival and overall survival (Nadin et al. 2007) .
At this point, we do not want to be over speculative since the number of patients entered into our study was low; however, the results on the value of HSPB1 as a predictive factor to cisplatin chemotherapy in patients with advanced cervical cancer are encouraging. In a recent article, other molecular marker (aldehyde dehydrogenase 1, converting retinol to retinoic acid) has been found as a predictive marker of chemoresistance in cervical cancer patients treated with neoadjuvant chemotherapy (Xie et al. 2016 ). In addition, Zhu et al. (2016) have reported that in cervical cancer patients treated with cisplatin-based neoadjuvant chemotherapy, high levels of mTOR, HIF-1α, c-Myc, and PKM2 were found associated with a positive chemotherapy response. We are hoping that in the future these molecular markers can be used to predict the response of cancer patients to cisplatin-based chemotherapy.
Our study revealed that in most cases, the cisplatin neoadjuvant chemotherapy was not significantly affecting the expression levels of MSH2, p16, and p53. Only nuclear NUPR1 levels tended to decrease. We did not find a significant correlation between high p16 levels and poor response to cisplatin treatment in vivo; nevertheless, the results show a tendency that might confirm the findings of Li et al. (2016) performed in SiHa cells, and are therefore interesting to be studied further. MSH2 was reported to be highly expressed during cell stress when the phosphorylated HSPB1 translocates to the nucleus, both taking part in the mismatch repair system (Nadin et al. 2007; Castro et al. 2015) ; furthermore, the protein in the heterocomplex with MSH6 was found to be required for cisplatin sensitivity (Sawant et al. 2015) . We therefore hypothesized that up-regulated MSH2 could be a possible predictor for good response to chemotherapy. However, in the present study, we observed a slight tendency toward poor response of the patients when the protein was highly expressed in the prechemotherapy biopsies. Finally, the expression of the other two molecular markers examined, p53 and NUPR1, were not associated with the response to cisplatin neoadjuvant chemotherapy.
In conclusion, our study supports the importance of HSPB1 in relationship to chemo resistance to cisplatin induction chemotherapy in patients with cervical cancer. Further studies should be directed to increase the number of patients to validate the results and to explore the possible molecular pathways implicated using cervical cancer cells.
